Not provided
Not provided
Not provided
Not provided
Not provided
lack of funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Dexamethasone is a medication that has been shown to have clear anti-nausea, anti-inflammatory, and painkilling properties. Dexamethasone is currently used to manage postoperative symptoms of a variety of surgical procedures. However, its effect has not been validated for scleral buckling surgery, which is used to treat retinal detachment, a medical emergency that can lead to permanent blindness. In this study, the investigators will randomly administer dexamethasone to half of scleral buckling surgery patients, and a placebo to the other half. The investigators will then compare the postoperative symptoms of the two groups in order to determine whether dexamethasone should be used for scleral buckling surgeries.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dexamethasone | Experimental | Subjects receive intravenous intraoperative dexamethasone |
|
| Saline solution | Placebo Comparator | Subjects receive intravenous intraoperative normal saline solution |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate Injection | Drug | 8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Subjective Level of Postoperative Nausea | Assessed through patient survey, measured by 10cm visual analogue scale | At 1 and 7 days post-surgery |
| Subjective Level of Postoperative Pain | Assessed by patient survey, measured by Wong-Baker FACES Pain Rating Scale | 1 and 7 days post-surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Subjective rating of post-operative lid edema | Assessed by investigator, rated "mild", "moderate", or "severe" | At 1 and 7 days post-surgery |
| Subjective rating of postoperative chemosis | Assessed by investigator, recorded as "mild", "moderate", or "severe" |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark Mandelcorn, MD FRCSC | University Health Network, Toronto | Principal Investigator |
| Rajeev Muni, MD FRCSC | Unity Health Toronto | Principal Investigator |
| Daniel B Rootman, MSc MD | University of Toronto | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Michael's Hospital | Toronto | Ontario | M5C 2T2 | Canada | ||
| Toronto Western Hospital |
Not provided
| ID | Term |
|---|---|
| D012163 | Retinal Detachment |
| D014839 | Vomiting |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C004180 | dexamethasone 21-phosphate |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Saline Injection | Drug | 2cc of 0.9% normal saline, IV injection, 1-time dose during surgery |
|
| 1 and 7 days post-surgery |
| Toronto |
| Ontario |
| M5T 2S8 |
| Canada |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D017670 |
| Sodium Compounds |